Armstrong Quoted On Expectations For New Biosimilar Bill

Specialty Pharma News

Mark Armstrong, a Member of the Firm in the Health Care and Life Sciences practice of Epstein Becker Green Wickliff & Hall in Houston, was quoted on the probability that a stand-alone biosimilar bill will be introduced soon in Congress.

In the article, "Reform Stalls, Expectations Are High For Another Stand-Alone Biosimilar Bill," Armstrong said it's likely a new biosimilar bill will be introduced because "there is enough bipartisan support overall, and there is enough interest in getting the legislation passed." In addition, while there are some aspects of the legislation — such as the length of the data-exclusivity period — that need to be agreed on, "there is sufficient common ground to get this done."

Armstrong added that a bill with a 12-year exclusivity period would probably have a good chance of passage.